Scientist have been facing numerous challenges in the development of an effective therapeutic strategy for the treatment of COVID-19 pneumonia. Several studies have suggested that improving patient immunity and reducing lung injury induced by COVID -19 could be effective in treating the patients with COVID-19. Our clinical study, involving a small sample size of seven patients demonstrated that nebulization mesenchymal stem cell (MSCs)-derived exosomes is a novel method that could be utilized in the treatment of COVID-19 pneumonia. Nebulization of MSC-derived exosomes did not induce acute allergic and secondary allergic reactions. It could promote the absorption of pulmonary lesions, and reduce the time of hospitalization for minor cases of COVID-19 pneumonia. Nebulization of MSC-derived exosomes is a safe, effective, and simple method. Nebulization of MSC-derived exosomes from the beginning of the treatment could be more beneficial to the patients.

- Journal
- Articles
- Author Center
- Society
Editorial Board
The ESMED Editorial Board is comprised of experts from around the world.
Meet the community
See what our members have been working on.
Membership
Join ESMED for access to member-only content, congress discounts, and more.
- Policy